10 min

Dual-Action T Cell Receptor Therapy for Solid Tumours with Katrien Reynders-Frederix of Pan Cancer T BioInnovation Spotlight

    • Life Sciences

Despite the successes of therapies like Kymriah and Yescarta against blood cancers, solid tumours remain difficult to treat. Finding appropriate molecular targets such as cancer-specific receptors is an ongoing challenge, while the physical environment of a solid tumour also plays a role in suppressing immune responses within it. That said, immunotherapy/cell therapy, like chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies, has shown amazing promise in treating cancer patients where traditional therapies have failed.
https://pancancer-t.com/ (Pan Cancer T) is a spinout from https://www.erasmusmc.nl/en/cancer-institute/patient-care (Erasmus MC Cancer Institute) in Rotterdam, the Netherlands. They are developing dual-action TCR cell therapies, a next-generation treatment for solid cancer that targets both the tumour and the immunosuppressive environment that they present.
In this episode of BioInnovation Spotlight, Katrien Reynders-Frederix talks about the novel approach to TCR therapy at Pan Cancer T, her personal journey from biology to business, and why she wants to make a difference for patients.
Pan Cancer T was founded by Prof. Reno Debets and Dr Dora Hammerl, and is supported by Thuja Capital, Van Herk Ventures, and Swanbridge Capital.

Despite the successes of therapies like Kymriah and Yescarta against blood cancers, solid tumours remain difficult to treat. Finding appropriate molecular targets such as cancer-specific receptors is an ongoing challenge, while the physical environment of a solid tumour also plays a role in suppressing immune responses within it. That said, immunotherapy/cell therapy, like chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies, has shown amazing promise in treating cancer patients where traditional therapies have failed.
https://pancancer-t.com/ (Pan Cancer T) is a spinout from https://www.erasmusmc.nl/en/cancer-institute/patient-care (Erasmus MC Cancer Institute) in Rotterdam, the Netherlands. They are developing dual-action TCR cell therapies, a next-generation treatment for solid cancer that targets both the tumour and the immunosuppressive environment that they present.
In this episode of BioInnovation Spotlight, Katrien Reynders-Frederix talks about the novel approach to TCR therapy at Pan Cancer T, her personal journey from biology to business, and why she wants to make a difference for patients.
Pan Cancer T was founded by Prof. Reno Debets and Dr Dora Hammerl, and is supported by Thuja Capital, Van Herk Ventures, and Swanbridge Capital.

10 min